{"groups":[{"description":"Group 1 (Oncotype DX recurrence score =\\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"FG000","title":"Arm A"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"FG001","title":"Arm B"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"FG002","title":"Arm C"},{"description":"Group 3 (Oncotype DX recurrence score \\>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"FG003","title":"Arm D"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1629"},{"groupId":"FG001","numSubjects":"3458"},{"groupId":"FG002","numSubjects":"3449"},{"groupId":"FG003","numSubjects":"1737"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"172"}],"type":"No On-study Data"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"}],"type":"Ineligible"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"55"},{"groupId":"FG002","numSubjects":"131"},{"groupId":"FG003","numSubjects":"245"}],"type":"No Follow-up Data"},{"achievements":[{"groupId":"FG000","numSubjects":"1619"},{"groupId":"FG001","numSubjects":"3399"},{"groupId":"FG002","numSubjects":"3312"},{"groupId":"FG003","numSubjects":"1389"}],"comment":"Patients analyzed in the main analysis","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"59"},{"groupId":"FG002","numSubjects":"137"},{"groupId":"FG003","numSubjects":"348"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients needed to be preregistered to the trial for ONCOTYPE recurrence score test, patients then were assigned or randomized to one of the four arms based on the recurrence score.","recruitmentDetails":"This study was activated on April 7, 2006 and closed to registrations on October 6, 2010. A total of 11,232 patients were preregistered for Recurrence Score evaluation and 10,273 proceeded to register on the study."}